Opendata, web and dolomites

LEGACy SIGNED

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LEGACy project word cloud

Explore the words cloud of the LEGACy project. It provides you a very rough idea of what is the project "LEGACy" about.

none    celac    extended    south    strategy    multiple    helicobacter    multicentre    countries    legacy    globally       central    similarly    positive    rates    treatments    differences    omics    susceptibility    pylori    location    respectively    intervention    epidemiological    death    secondary    disease    arrival    strategies    outcomes    standpoint    health    virus    stage    prognosis    incidence    prevention    conceptual    worldwide    infection    makeup    genome    histological    deaths    dietary    vary    total    cancer    ebv    contrast    sexes    integrative    gc    levels    24    lowest    patients    molecular    sharp    revolutionized    locally    eastern    highest    plays    databases    urgent    primary    personalized    medicine    bacterium    mortality    asia    723    gcs    model    populations    public    barr    participating    largely    epidemiology    men    10    genetic    asian    poorly    northern    gastric    international    women    america    epstein    biology    strains    tumour   

Project "LEGACy" data sheet

The following table provides information about the project.

Coordinator
FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA 

Organization address
address: AV MENENDEZ PELAYO 4
city: VALENCIA
postcode: 46010
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 3˙993˙056 €
 EC max contribution 3˙577˙431 € (90%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA ES (VALENCIA) coordinator 638˙315.00
2    IPATIMUP - INSTITUTO DE PATOLOGIA E IMUNOLOGIA MOLECULAR DA UNIVERSIDADE DO PORTO PCUP PT (PORTO) participant 660˙162.00
3    FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON ES (BARCELONA) participant 550˙000.00
4    STICHTING VUMC NL (AMSTERDAM) participant 471˙875.00
5    PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE CL (SANTIAGO) participant 305˙235.00
6    ANAXOMICS BIOTECH, S.L. ES (BARCELONA) participant 275˙218.00
7    CABALLERO LLANO CARMELO CESAR PY (ASUNCION) participant 216˙093.00
8    EUROPEAN CANCER PATIENT COALITION BE (BRUXELLES) participant 197˙750.00
9    ALEXANDER FLEMING SA AR (BUENOS AIRES) participant 131˙625.00
10    UNIVERSITAET LEIPZIG DE (LEIPZIG) participant 131˙156.00
11    Instituto Nacional de Cancerología MX (MEXICO) participant 0.00

Map

 Project objective

Globally, gastric cancer (GC) is the third leading cause of cancer death in both sexes worldwide (723,000 deaths, 8.8% of the total). The highest estimated mortality rates are in Eastern Asia (24 per 100,000 in men, 9.8 per 100,000 in women), the lowest in Northern America (2.8 and 1.5, respectively). High mortality rates are also present in both sexes in Central and Eastern Europe, and in Central and South America. None strategies have improved prognosis in locally advanced stage III and IV GC. Therefore, an urgent intervention is needed. Epidemiological and molecular features of GCs can vary widely according to their histological type, location and genetic makeup of the tumour. The reasons behind these differences are multiple and complex and may include genetic susceptibility, strains of the bacterium Helicobacter pylori (H. pylori) and dietary factors. In particular, H. pylori infection plays a relevant role in GC incidence. Similarly, about 10% of GC patients are positive for the infection of the Epstein Barr Virus (EBV) . Most studies and current international databases on late-stage/advanced GC are largely based on Asian populations, in sharp contrast tumour biology and genome of EU and CELAC countries is poorly known. From a public health standpoint, prevention can be conducted at three levels: primary, secondary, and for improving outcomes at the advanced stage of disease. In recent years, the arrival of personalized medicine has revolutionized available treatments for cancer patients. The primary aim of LEGACY project is to improve GC outcomes by applying personalized medicine at the three levels of prevention: in EU and CELAC countries participating in this multicentre case-control study based on an “omics integrative epidemiology” conceptual model as a strategy to be extended worldwide.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LEGACY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LEGACY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More